J&J bails on Geron cancer drug

Sep 27, 2018

Johnson & Johnson's Janssen Biotech will end a licensing partnership with Geron Corp., returning rights to the biotech’s sole product candidate, imetelstat.

Janssen had entered into the agreement in 2014 with California-based Geron to develop and commercialize imetelstat in oncology, including hematologic myeloid malignancies.

According to Janssen’s press release, the decision not to continue the collaboration is the “result of a strategic portfolio evaluation and prioritization of assets within the robust Janssen portfolio.”

Bloomberg reports that the move wiped out $750 million in market value for Geron.

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments